Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).

被引：0

作者：

Barthelemy, Philippe

Loriot, Yohann

Voog, Eric

Eymard, Jean Christophe

Ravaud, Alain

Flechon, Aude

Jaillon, Christine Abraham

Chasseray, Matthieu

Lorgis, Veronique

Hilgers, Werner

Gobert, AurElien

Le Moulec, Sylvestre

Simon, Camille

Nicolas, Emanuel

Escande, Anne

Pouessel, Damien

Josse, Constant

Solbes, Marie-Noelle

Lambert, Prisca

Thibault, Constance

机构：

[1] Inst Cancerol Strasbourg Europe, Strasbourg, France

[2] Gustave Roussy, Villejuif, France

[3] Clin Victor Hugo Ctr Jean Bernard, Le Mans, France

[4] Inst Cancerol Jean Godinot, Reims, France

[5] Bordeaux Univ, Bordeaux Univ Hosp, Bordeaux, France

[6] Ctr Leon Berard, Lyon, France

[7] Foch Hosp, Suresnes, France

[8] Ctr Finisterien Radiotherapie & Oncol Clin Pasteu, Brest, France

[9] Inst Cancerol Bourgogne, Dijon, France

[10] Avignon Provence Canc Inst, Avignon, France

[11] St Gregoire Hosp, St Gregoire, France

[12] Clin Marzet, Pau, France

[13] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France

[14] Univ Hosp Nimes, Nimes, France

[15] Clin Ste Anne, Strasbourg, France

[16] Inst Claudius Regaud IUCT Oncopole, Toulouse, France

[17] eXYSTAT, Malakoff, France

[18] Merck Sante SAS, Lyon, France

[19] Pfizer Oncol, Paris, France

[20] Univ Paris Cite, Hop Europeen Georges Pompidou, AP HP Ctr, Inst Canc Paris CARPEM, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

471

引用

页数：1

共 50 条

[1] AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)
Barthelemy, P.
Loriot, Y.
Flechon, A.
Goupil, M. Gross
Voog, E.
Eymard, J-C.
Lorgis, V.
Pouessel, D.
Francois, L.
Sajous, C.
Bouju, D. Chocteau
Guillot, A.
Long, J.
Amela, E.
Josse, C.
Solbes, M-N.
Lambert, P.
Thibault, C.
ANNALS OF ONCOLOGY, 2023, 34 : S1211 - S1212
[2] Updated results from AVENANCE: Real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of subsequent treatment.
Barthelemy, Philippe
Loriot, Yohann
Thibault, Constance
Gross-Goupil, Marine
Eymard, Jean Christophe
Voog, Eric
Abraham Jaillon, Christine
Le Moulec, Sylvestre
Chasseray, Matthieu
Gobert, Aurelien
Auberger, Benjamin
Viala, Caroline
Cabart, Mathilde
Kazan, Eyad
Lorgis, Veronique
Hilgers, Werner
Josse, Constant
Lambert, Prisca
Solbes, Marie-Noelle
Flechon, Aude
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 561 - 561
[3] Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)
Barthelemy, P.
Thibault, C.
Voog, E.
Eymard, J-C.
Ravaud, A.
Flechon, A.
Jaillon, C. Abraham
Hilgers, W.
Le Moulec, S.
Chasseray, M.
Pouessel, D.
Amela, Y. E.
Lorgis, V.
Nicolas, E.
Kazan, E.
Denechere, G.
Solbes, M-N.
Lambert, P.
Loriot, Y.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1341 - S1342
[4] Avelumab first-line (1L) maintenance therapy in advanced urothelial carcinoma: Final analysis from a real-world study in the UK.
Jones, Robert Jones
Shah, Yatri
Birtle, Alison Jane
Challapalli, Amarnath
Chan, Joachim
Enting, Deborah
Hudson, Andrew
Linch, Mark David
Otter, Sophie
Protheroe, Andrew
Sharma, Anand
Turner, Rufus
Chengat Prakashbabu, Bhagyalakshmi
Rice, Wendy
Jedy-Agba, Elima Enaji
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
[5] Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment
Barthelemy, Philippe
Thibault, Constance
Flechon, Aude
Gross-Goupil, Marine
Voog, Eric
Eymard, Jean-Christophe
Abraham, Christine
Chasseray, Matthieu
Lorgis, Veronique
Hilgers, Werner
Gobert, Aurelien
Le Moulec, Sylvestre
Simon, Camille
Nicolas, Emanuel
Escande, Anne
Pouessel, Damien
Mouillet, Guillaume
Josse, Constant
Solbes, Marie-Noelle
Lambert, Prisca
Loriot, Yohann
EUROPEAN UROLOGY ONCOLOGY, 2025, 8 (02): : 407 - 416
[6] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Gupta, S.
Climent Duran, M. A.
Sridhar, S.
Powles, T. B.
Bellmunt, J.
Tyroller, K.
Guenther, S.
di Pietro, A.
Grivas, P.
ANNALS OF ONCOLOGY, 2023, 34 : S1207 - S1207
[7] Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)
Powles, T. B.
Sridhar, S.
Bellmunt, J.
Sternberg, C.
Grivas, P.
Hunter, E.
Dezfouli, M.
Salter, M.
Powell, R.
Dring, A.
Green, J.
Akoulitchev, A.
Amezquita, R.
Ching, K.
Pu, J.
Deng, S.
di Pietro, A.
Davis, C. B.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1442 - S1442
[8] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with histological subtypes
Loriot, Yohann
Gupta, Shilpa
Powles, Thomas
Grivas, Petros
Petrylak, Daniel P.
Tyroller, Karin
Jacob, Natalia
Hoffman, Jason
Bellmunt, Joaquim
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval.
Li, Haojie
Herms, Lisa
Leong, Traci
Conkling, Paul R.
Franco, Sonia
Singhal, Puneet
Mamtani, Ronac
Bupathi, Manojkumar
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[10] Avelumab first-line (1 L) maintenance for advanced urothelial carcinoma (aUC): Results from patients with ≥12 months of treatment in JAVELIN Bladder 100
Aragon-Ching, Jeanny B.
Grivas, Petros
Loriot, Yohann
Bellmunt, Joaquim
Pook, David W.
Wang, Jing
Michelon, Elisabete
di Pietro, Alessandra
Powles, Thomas
Sridhar, Srikala S.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 138 - 139

← 1 2 3 4 5 →